CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.980
+0.080 (8.88%)
Apr 29, 2026, 9:30 AM EDT - Market open

CytoMed Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
12153956--
Upgrade
Market Cap Growth
-59.81%-60.73%-30.55%---
Upgrade
Enterprise Value
9143549--
Upgrade
Last Close Price
0.901.333.404.90--
Upgrade
PS Ratio
15.9123.02106.38146.86--
Upgrade
PB Ratio
2.092.895.926.63--
Upgrade
P/TBV Ratio
2.133.096.046.64--
Upgrade
EV/Sales Ratio
14.0420.3393.59127.72--
Upgrade
Debt / Equity Ratio
0.070.070.050.047.201.26
Upgrade
Net Debt / Equity Ratio
-0.23-0.23-0.50-0.764.500.28
Upgrade
Net Debt / EBITDA Ratio
0.420.421.612.47-1.80-0.52
Upgrade
Net Debt / FCF Ratio
0.370.371.102.38-1.41-0.32
Upgrade
Asset Turnover
0.100.100.050.060.060.02
Upgrade
Inventory Turnover
0.090.090.040.010.020.01
Upgrade
Quick Ratio
3.143.148.3912.830.390.86
Upgrade
Current Ratio
5.175.179.8914.080.601.12
Upgrade
Return on Equity (ROE)
-50.28%-50.28%-24.86%-69.87%-197.08%-133.79%
Upgrade
Return on Assets (ROA)
-29.31%-29.31%-17.44%-27.30%-20.55%-21.98%
Upgrade
Return on Capital Employed (ROCE)
-58.20%-58.20%-33.10%-33.00%-175.10%-55.30%
Upgrade
Earnings Yield
-29.06%-20.09%-4.70%-5.54%--
Upgrade
FCF Yield
-31.86%-21.88%-7.68%-4.81%--
Upgrade
Buyback Yield / Dilution
-0.93%-0.93%-8.56%-34.30%-14.14%-17.59%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.